Get started
Author

Ahmad Hormati

SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial
2019 · Shahin Merat, Shahin Merat, et al. · Clinical Infectious Diseases · 28
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment
2020 · Hossein Poustchi, Sara Majd Jabbari, et al. · Journal of Gastroenterology and Hepatology · 25
Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial
2021 · Shahin Merat, Amir-Houshang Sharifi, et al. · Clinical Infectious Diseases · 18
PDF
Efficacy of Pyloshot in combination with standard four‐drug antimicrobial treatment for Helicobacter pylori eradication: A randomized clinical trial
2024 · Hossein Azad, Ahmad Hormati, et al. · JGH Open · 1
PDF
The Investigation of the Effect of a Dandelion Herbal Capsule (GHASEDAK Capsule) on Fibrosis and Liver Function in NAFLD: A Randomized, Double Blind, Placebo-controlled, Single-center Clinical Trial
2026 · Hoda Abolhasani, Mohammad Reza Ghadir, et al. · Current Drug Therapy
THU-162-The combination of sofosbuvir and daclatasvir is well tolerated and extremely effective in treating patients with hepatitis C with severe renal impairment including hemodialysis patinets
2019 · Shahin Merat, Amir-Houshang Sharifi, et al. · Journal of Hepatology
Works count: 6
Citation count: 72
H-index: 3
I10-index: 3
Year
Topic
Type